Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

This study has been completed.
Sponsor:
Collaborator:
ICOS Corporation
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00386009
First received: October 9, 2006
Last updated: July 1, 2009
Last verified: July 2009

October 9, 2006
July 1, 2009
October 2006
May 2008   (final data collection date for primary outcome measure)
Change From Baseline to 12 Week Endpoint in Detrusor Pressure at Peak Urinary Flow Rate (PdetQmax) [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00386009 on ClinicalTrials.gov Archive Site
  • Change From Baseline to 12 Week Endpoint in Peak Urinary Flow Rate (Qmax) Measured During Free-Flow Studies [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline to 12 Week Endpoint in Mean Urinary Flow Rate (Qave) Measured During Free-Flow Studies [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline to 12 Week Endpoint in Volume of Voided Urine (Vcomp) Measured During Free-Flow Studies [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline to 12 Week Endpoint in Postvoid Residual Volume (PVRcath) Measured During Free-Flow Studies [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline to 12 Week Endpoint in Total Bladder Capacity Measured During Free-Flow Studies [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline to 12 Week Endpoint in Bladder Voiding Efficiency (BVE) Measured During Free-Flow Studies [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline to 12 Week Endpoint in Peak Urinary Flow Rate (Qmax) Measured During Pressure-Flow Studies [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline to 12 Week Endpoint in Mean Urinary Flow Rate (Qave) Measured During Pressure-Flow Studies [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline to 12 Week Endpoint in Volume of Voided Urine (Vcomp) Measured During Pressure-Flow Studies [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline to 12 Week Endpoint in Maximum Detrusor Pressure (Max Pdet) Measured During Pressure-Flow Studies [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline to 12 Week Endpoint in Bladder Contractility Index (BCI) Measured During Pressure-Flow Studies [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline to 12 Week Endpoint in Bladder Outlet Obstruction Index (BOOI) Measured During Pressure-Flow Studies [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Presence of Involuntary Detrusor Contractions During Bladder Filling [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline to 12 Week Endpoint in Bladder Volume at First Involuntary Detrusor Contraction [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Total Score [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Clinically Adverse and Statistically Significant Changes From Baseline to 12 Week Endpoint in Laboratory Tests [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
 
Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

The purpose of this study is to evaluate the function of the bladder and urethra during urinary storage or voiding in men with signs and symptoms of benign prostatic hyperplasia treated with either placebo or tadalafil.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Benign Prostatic Hyperplasia
  • Drug: Tadalafil
    20 mg tadalafil tablet taken by mouth once a day for 12 weeks.
    Other Names:
    • LY450190
    • Cialis
    • IC351
  • Drug: Placebo
    Placebo tablet taken by mouth once a day for 12 weeks.
  • Placebo Comparator: 1
    Placebo
    Intervention: Drug: Placebo
  • Active Comparator: 2
    tadalafil
    Intervention: Drug: Tadalafil
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
May 2008
May 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Men 40 years of age or older with Lower Urinary Tract Symptoms (LUTS) with a total International Prostate Symptom Score (IPSS) greater than or equal to 13 at Visit 1.
  • Agree not to use any other approved or experimental medications for Benign Prostate Hyperplasia (BPH)-Lower Urinary Tract Symptoms, including alpha blockers, 5-alpha reductase inhibitors, PDE5 inhibitors, or herbal preparations at any time during the study.
  • Have not taken finasteride or dutasteride therapy for at least 4 months prior to Visit 2; have not taken any other LUTS therapy (including herbal preparations) or PDE5 inhibitors for at least 4 weeks prior to Visit 2.
  • Have had BPH-LUTS for greater than 6 months prior to Visit 1.

Exclusion Criteria:

  • Any pelvic surgical procedure on the urinary tract, including minimally invasive BPH-LUTS therapies and penile implant surgery.
  • History of urethral obstruction due to stricture, valves, sclerosis, or tumor.
  • Current neurologic disease or condition associated with neurogenic bladder (for example, Parkinson's disease, multiple sclerosis).
  • History of cardiac conditions including myocardial infarction, bypass surgery, angioplasty or stent placement for a specified time before starting the study.
  • History of angina requiring treatment with nitrates.
  • Prostate Specific Antigen (PSA) greater than 10 nanogram/milliliter (ng/ml) at Visit 1.
Male
40 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Greece,   Portugal
 
NCT00386009
11233, H6D-MC-LVHK
No
Chief Medical Officer, Eli Lilly
Eli Lilly and Company
ICOS Corporation
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP